Merck gets FDA priority review for Recarbrio in HABP/VABP

This article was originally published here

The supplemental New Drug Application (sNDA), which has been filed by the company and accepted by the regulator, is seeking approval for using Recarbrio for treating adult patients

The post Merck gets FDA priority review for Recarbrio in HABP/VABP appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply